Comparison of the effect and side effects of two way of progesterone suppository use in IVF cycles

comparison of the effect of cyclogess usage in vaginal or rectal form for luteal phase support on pregnancy rate of ICSI cycles and the rate of side effects and patients convenient in these two ways.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138807192568N1

Enrollment

150

Registered

2011-04-20

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

artificial fertilization. Complication associated with artificial fertilization, unspecified

Interventions

Intervention 1: administeration of cyclogest suppository 400 mg twice a day in rectal form for intervention group. Intervention 2: Administeration of cyclogest suppository 400 mg twice a day in vagin

Treatment - Drugs

administeration of cyclogest suppository 400 mg twice a day in rectal form for intervention group

Administeration of cyclogest suppository 400 mg twice a day in vaginal form for control group

Eligibility

Sex/Gender

Female

Age

20 Years to 37 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are : 20-37 years old wemon candidate for first ICSI cycle Exclusion criteria : FSH>8ng/ml ,Hypotyroidy,hyperprolactinemia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Biochemical pregnancy. Timepoint: 2 weeks after drug administration. Method of measurement: blood sample - BHCG.	—

Secondary

Measure	Time frame
Perineal itching due to Cyclogest use in vaginal or rectal form. Timepoint: 2 weeks after start of drug. Method of measurement: Ask of patients.;Vaginal discharge due to cyclogest use in vaginal and rectal form. Timepoint: 2 weeks after drug administration. Method of measurement: Ask of pationts.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHaleh Rahmanpour

Valiasre reaserch center

haleh509@zums.ac.ir+98 21 6658 1575

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026